Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941016 | 0.94 | CNR1 (0.46) | SLC22A12CNR1CNR2ACHEDYRK1A | |
| SCHEMBL1942089 | 0.93 | CNR2 (0.45) | SLC22A12CNR1CNR2ACHEDYRK1A | |
| SCHEMBL1941007 | 0.81 | CNR2 (0.48) | CNR1CNR2HRH3NPC1RAB9A | |
| SCHEMBL1940064 | 0.81 | SLC22A12 (0.46) | SLC22A12ADORA1ADORA3ADORA2A | |
| SCHEMBL1939994 | 0.79 | HTR3A (0.53) | CNR1CNR2DYRK1AHRH3NPC1 | |
| SCHEMBL1940429 | 0.79 | KHK (0.47) | DYRK1AHRH3CYP2D6 | |
| SCHEMBL1939148 | 0.77 | SLC22A12 (0.49) | SLC22A12CNR2ADORA1ADORA3ADORA2A | |
| SCHEMBL2306802 | 0.76 | SLC22A12 (0.50) | SLC22A12CNR1CNR2ACHEADORA1 | |
| SCHEMBL1940284 | 0.75 | HRH3 (0.43) | CA12CA9DYRK1AHRH3CYP2D6 | |
| SCHEMBL1939452 | 0.75 | HRH3 (0.43) | CA12CA9DYRK1AHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173679-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2012-05-08 | — | — | US | disclosed |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2011-09-29 | — | — | US | disclosed |
| CN-101080395-B | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | THERAMEX SAM LAB | 2011-08-17 | — | — | CN | disclosed |
| US-7977364-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2011-07-12 | — | — | US | disclosed |
| EP-1812404-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | THERAMEX (MC) | 2011-06-15 | — | — | EP | disclosed |
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERAMEX (FR) | 2009-01-22 | — | — | US | disclosed |
| CN-101080395-A | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | THERAMEX (MC) | 2007-11-28 | — | — | CN | disclosed |
| EP-1812404-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006040351-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2006-04-20 | — | — | WO | disclosed |
| EP-1647549-A1 | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents | LABORATOIRE THERAMEX (MC) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | ESR1, ESR2, GPER1 | CA12 4002/4885CA9 2904/4885SLC22A12 3816/4885 |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | ESR1, ESR2, GPER1 | CA12 4002/4885CA9 2904/4885SLC22A12 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.